Loading
Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)
The company behind devimistat, a drug against cancer cell metabolism that failed its phase 3 trials in pancreatic cancer and leukaemia.
Also called: Rafael Pharmaceuticals
Overview
Rafael Pharmaceuticals, majority owned by Rafael Holdings, developed devimistat (CPI-613) for pancreatic cancer and acute myeloid leukaemia. After both phase 3 trials missed their endpoints in 2021 and 2022 the company was renamed Cornerstone Pharmaceuticals and refocused its pipeline.
Headquarters
Cranbury, New Jersey, United States, US
Scorecard
All companies#413of 1245 companies, score 8
- modalities +2
- registry trials +9
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 21 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Products
1NegativeSmall-molecule inhibitor of mitochondrial metabolism (PDH and KGDH)
Devimistat tried to starve pancreatic cancer cells of their energy supply alongside chemotherapy; the phase 3 AVENGER 500 trial found no survival gain.
Connected
4Similar pages
cancers
drugs
NegativeSmall-molecule inhibitor of mitochondrial metabolism (PDH and KGDH)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
cornerstonepharma.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Apply the update bot's proposals (PR 16) · diff · file
Sourced, not expert-reviewed